Goldman Sachs
EIGR

Goldman Sachs’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Goldman Sachs’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-14
Closed -$7K – 7391
2015
Q3 		$7K Sell
14
-3
-18% -$1.59K ﹤0.01% 7175
2015
Q2 		$10K Buy
17
+7
+70% +$19.4K ﹤0.01% 7158
2015
Q1 		$87K Buy
+10
New +$87.4K ﹤0.01% 6490

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's EIGR Position: Q3 2023 in Review

Goldman Sachs sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 390 shares — an estimated $8.24K sold.

Goldman Sachs first reported a position in EIGR in Q1 2014 and held it in 30 quarters. The position peaked at $6.73M in Q4 2020. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

  • Goldman Sachs reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Goldman Sachs sold 390 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $8.24K.
  • Goldman Sachs first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 30 quarters.
  • Goldman Sachs's Eiger BioPharmaceuticals, Inc. position peaked at $6.73M in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.